Liquid Biopsy in Oncology: Revolutionizing Early Detection and Monitoring

Author(s)	Dr. Nandini Goswami, Dr. Shanila Thankam Suresh, Dr. Jona Joy, Dr. Alvina Christiana
Country	India
Abstract	Background: Despite being the gold standard for molecular profiling and cancer diagnosis, traditional tissue biopsy has drawbacks such as invasiveness, procedural hazards, and difficulties capturing tumor heterogeneity. A minimally invasive method for thorough tumor profiling, liquid biopsy is based on the examination of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other indicators in blood or bodily fluids. Clinical use has accelerated due to regulatory approvals of ctDNA-based tests including FoundationOne Liquid CDx and Guardant360 CDx, and ongoing trials are investigating its potential for minimal residual disease (MRD) surveillance and early identification.
Keywords	Keywords: Liquid biopsy; Circulating tumor DNA (ctDNA); FoundationOne Liquid CDx; Guardant360 CDx; Early cancer detection; Minimal residual disease (MRD); Oncology; NCCN guidelines; ASCO recommendations; Clinical trials
Field	Biology > Genetics / Molecular
Published In	Volume 7, Issue 5, September-October 2025
Published On	2025-09-30
DOI	https://doi.org/10.36948/ijfmr.2025.v07i05.56716

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research